Glucose monitoring has evolved beyond its traditional role in diabetes management, with an increasing number of people using these devices to track blood sugar levels for overall health and wellbeing.

Broad availability of the twiist and Eversense 365 integrated product is expected by March 2026, as per the company.

The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Share on Pinterest The Signos system can be used alone, in combination with, or after GLP-1 drugs or bariatric surgery. Photography courtesy of Signos The FDA cleared the first glucose monitoring ...

This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of ...